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Abstract
Tumor suppressor genes that perform apparently generic cellular functions nonetheless
cause tissue-specific syndromes in the human population when they are mutated in the
germline. The two major hereditary breast/ovarian cancer predisposition genes, BRCA1 and
BRCA2, appear to participate in a common pathway that is involved in the control of
homologous recombination and in the maintenance of genomic integrity. How might such
functions translate into the specific suppression of cancers of the breast and ovarian
epithelia? Recent advances in the study of BRCA1 and BRCA2, discussed herein, have
provided new opportunities to address this question.
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Introduction
Familial breast or ovarian cancer predisposition syn-
dromes have long been recognized. Their genetic bases
have become clear with the cloning of two major disease
susceptibility genes, BRCA1 and BRCA2, termed herein
‘BRCA’ genes [1–4]. Each has characteristics of a tumor
suppressor gene: inheritance within affected families
follows an autosomal-dominant pattern of inheritance; and
loss of heterozygosity (LOH) at the relevant gene locus is
seen in familial tumors, with retention of the disease-pre-
disposing allele [5–8]. The spectrum of disease-associ-
ated mutations includes frequent truncating mutations and
less frequent missense mutations. Although LOH is fre-
quently detected at the BRCA1 or BRCA2 locus in spo-
radic breast cancer, the retained allele is almost always
wild-type [9,10]. Thus, in contrast to the causal role of
BRCA gene mutation in the hereditary syndrome, BRCA
gene mutation in sporadic breast or ovarian cancer
seldom conforms to Knudson’s model for tumor suppres-
sor genes [11]. Cancer risk in BRCA gene mutation carri-
ers may be increased modestly in other organs. However,
highly penetrant, early-onset, site-specific cancer is
restricted to the breast and ovary.
BRCA1 and  BRCA2 homologs have been detected in
several mammalian species, including the mouse. BRCA1
and BRCA2 are expressed ubiquitously [12–14]. Gene
targeting experiments in the mouse [15–22] have revealed
functional differences between true null and partial loss-of-
function (hypomorphic) mutant alleles of BRCA genes. If
these distinctions can be made in murine development,
the same might be true in human disease. At its simplest,http://breast-cancer-research.com/content/2/5/324
a hypomorphic BRCA allele might exhibit lower pene-
trance for cancer than a true null allele. Because of the rel-
ative scarcity of individual BRCA mutant alleles and the
existence of unidentified modifier genes, it has been diffi-
cult to estimate the penetrance of different disease-predis-
posing BRCA alleles. However, the position of a mutation
in the BRCA1 or BRCA2 gene can affect the relative inci-
dences of breast and ovarian cancer within a kindred
[23,24]. These observations suggest that the breast and
ovarian epithelia differ in their requirements for BRCA
gene function. Whether this is a qualitative or quantitative
difference is unknown.
BRCA1 germline mutations differ from those that affect
BRCA2 with regard to the relative risk of developing other
solid tumors. BRCA2 germline mutation carries an
increased risk for cancers of the prostate, pancreas, gall-
bladder/bile duct, and stomach, as well as for malignant
melanoma [25]. BRCA2 mutation also appears to confer
higher risks for male breast cancer [26]. BRCA1 mutation
confers a higher incidence of ovarian cancer than does
BRCA2 mutation [26]. There appear to be histologic dif-
ferences between BRCA1-linked and BRCA2-linked
breast tumors [27,28]. Taken together, these point to
subtle differences between BRCA1 and BRCA2 germline
mutations in their impact on tumorigenesis. At present, the
mechanistic basis of these differences is unknown.
Role of BRCA1 and BRCA2 in maintenance of
genome integrity
The  BRCA1 and  BRCA2 gene products (BRCA1 and
BRCA2, respectively) function in the maintenance of
genomic integrity, at least in part by cooperating with
recombinational repair proteins. Both BRCA1 and BRCA2
form a complex with Rad51, a protein that has an estab-
lished role in homologous recombination [17,29,30]. The
BRCA1, BRCA2, and Rad51 proteins are coexpressed in
the developing mouse embryo, and gene targeting of each
revealed similar lethal phenotypes of nullizygous mouse
embryos [14,16,17,31,32]. BRCA1, BRCA2, and Rad51
colocalized in S-phase nuclear foci in somatic cells, and
upon the axial element of the developing synaptonemal
complex of cells in meiotic prophase I [29,33]. The
BRCA1 and BRCA2 proteins were also found to be com-
plexed with one another in cell extracts [33], suggesting
that these proteins collaborate on a common pathway of
tumor suppression. A specific role for this complex in the
S phase was implied by the rapid relocalization of BRCA1,
BRCA2, and associated proteins to sites of DNA synthe-
sis after exposure of cells to certain DNA-damaging
agents in S phase [34,35]. The BRCA1 protein also inter-
acts with the Rad50/MRE11/NBS1 complex, implicated in
the response to double-stranded DNA breaks [36].
Functional data from the study of BRCA1- or BRCA2-
mutated mice has confirmed a role for these genes in the
maintenance of genomic integrity. Both BRCA2 and
BRCA1 homozygous mutant cells exhibit ionizing radiation
sensitivity, a frequent indicator of a DNA repair defect
[17,20]. BRCA2 or BRCA1 homozygous mutant mouse
embryonic fibroblasts (MEFs) from embryos reveal sponta-
neous chromosomal anomalies and chromosome break-
age, which is consistent with a recombination defect
[20,37]. A unique BRCA1 homozygous mutant embryonic
stem cell clone revealed reduced efficiency of gene con-
version in response to a site-specific double-stranded
DNA break [38]. A defect in gene targeting (a process
that is dependent on homologous recombination) in the
same embryonic stem cell clone was improved by re-
expression of wild-type BRCA1 [39]. BRCA1 or BRCA2
mutated cancer cell lines reveal abnormally delayed kinet-
ics of double-strand break repair (DSBR) [18,40]. Defini-
tive evidence linking BRCA1 function in DSBR with its
tumor suppressor role came from the finding that wild-
type, but not clinically defined mutant BRCA1 alleles, can
restore efficient DSBR to a BRCA1-mutated breast
cancer cell line [41]. The biochemical mechanisms of
action of BRCA1 and BRCA2 in DSBR have yet to be
determined. Where examined, BRCA mutant cells
revealed defects in homologous recombination, but not in
nonhomologous end-joining [22,27,38].
Although recombination would seem to be a unifying
theme in these processes, other repair functions, such as
the transcription-coupled repair of oxidative DNA damage,
are defective in some BRCA1-mutated cells [22,42].
BRCA1 also plays a role in the G2/M checkpoint
response to ionizing radiation, although this has not been
observed in all BRCA1-mutated cells [21,41]. BRCA1 or
BRCA2 homozygous mutation leads to severe aneuploidy,
accompanied by centrosome amplification [21,43].
Genomic instability is characteristic of cancer cells, and it
is not difficult to imagine that mutation in BRCA1 or
BRCA2 might accelerate tumorigenesis, for example
through promoting aneuploidy, chromosomal translocation
or LOH events. If BRCA gene functional inactivation desta-
bilizes the genome, tumor development might be com-
pressed into a shorter time frame. In diseases such as
breast or ovarian cancer, the incidence of which increases
with advancing age, the ‘mere’ acceleration of disease pro-
gression could contribute to the early onset of disease that
is characteristically seen in carriers of BRCA mutations.
However, this does not provide an obvious explanation of
the specifically increased risk of breast/ovarian cancer in
BRCA gene mutation carriers. The following sections
explore hypotheses that could account for this specificity.
Collaboration between repair and checkpoint
functions in tumorigenesis
BRCA1 and  BRCA2 nullizygous embryos die early in
development, with a severe growth deficit accompaniedBreast Cancer Research    Vol 2 No 5 Scully
by elevated expression of the p53-responsive cell cycle
inhibitor, p21 [16,44,45]. This suggests that not only
failed DNA repair, but also the cell’s response to that
failure might be relevant to BRCA gene biology. If BRCA1
and  BRCA2 are DNA repair genes, then the p53/p21-
mediated growth arrest seen in BRCA mutant tissue might
represent a ‘checkpoint’ response to spontaneous DNA
damage arising as a result of the failure of DNA repair
processes. The above-noted chromosome breakage syn-
drome, described in BRCA2 or BRCA1 homozygous
mutant MEFs, supports this idea [20,37].
These observations suggest a way to understand the role of
BRCA gene mutation in tumorigenesis. Perhaps loss of
BRCA gene function in an otherwise intact epithelial cell
might lead to its death or arrest, because of activation of
checkpoint functions. However, if BRCA gene mutation
were to occur within a cell that had already suffered inacti-
vation of critical DNA damage-responsive checkpoints, then
the abnormalities in DNA structure resulting from BRCA
gene loss might be tolerated, and might then manifest their
potential as accelerators of tumor progression. This hypoth-
esis would predict that checkpoint loss is a necessary pre-
cursor of BRCA gene inactivation in tumorigenesis.
Several recent developments in mouse models of BRCA-
linked disease support this hypothesis. BRCA1 or
BRCA2 mutant MEFs undergo growth arrest at early
passage [20,37]. Both p53-dependent and p53-indepen-
dent checkpoints appear to play a part in this growth
arrest [20,22,46]. Recently, by use of the Cre-lox system,
BRCA1 gene inactivation was achieved specifically in the
breast of the adult mouse [47]. Such mice developed late-
onset breast cancer, with frequent p53 mutation seen in
tumors. When these mice were re-examined on a p53+/–
genetic background, breast cancer was detected at
higher frequency and with earlier onset [47]. This model
indicates a permissive role for p53 mutation in BRCA-
linked disease. Hemizygosity in p53 was also found to
play a permissive role for breast tumor development in
BRCA1+/– mice that had been exposed to ionizing radia-
tion [48]. Mutation in p53 is common (occurring in approx-
imately 30%) in sproadic breast/ovarian cancer, but is
considerably more common (occurring in approximately
60%) in BRCA-linked disease [49]. BRCA-linked disease
has also been found to be associated with rare p53
mutant alleles, suggesting that novel p53 functions may
be lost in BRCA-linked tumorigenesis [46,50]. The full
spectrum of checkpoint(s) that are responsible for
restraining cells mutated for BRCA1 or BRCA2 from con-
tinued proliferation remains to be defined. One recently
identified candidate is the spindle checkpoint [46].
If  BRCA-linked disease requires inactivation of check-
point(s) followed by BRCA gene loss, then the tissue
specificity of BRCA-linked disease might arise from a spe-
cific predisposition of the breast and ovarian epithelium to
lose the function of such checkpoints. If so, the question
shifts sideways – what determines the timing of inactivation
of DNA damage checkpoints in breast/ovarian cancers?
Recombination and breast development
The breast epithelium undergoes distinct developmental
programs during puberty and pregnancy. During puberty,
in particular, rapid proliferation of breast tissue occurs,
and the progeny of this proliferative burst are retained
within the breast lobule. This is demonstrated by the
finding that lobules of the breast are clonal [51–53]. In
this way, breast epithelial cells have the potential to retain
‘memory’ of genetic alterations that occurred earlier in
breast development. In contrast, some other epithelia that
are characterized by rapid proliferation, such as the intesti-
nal epithelium, shed cells continuously.
Radiation exposure in young women – in atomic bomb
survivors or from iatrogenic causes – carries with it a
specifically increased risk of subsequent breast cancer
[54,55]. Women who were exposed to A bomb radiation
at less than 20 years of age developed breast cancer with
normal latency, suggesting that that risk was increased
but that disease progression was unaffected. More
recently, it became clear that A bomb exposure below the
age of 10 years, before the onset of puberty, increased
the risk of subsequent adult-onset breast cancer [56].
Perhaps this early impact of radiation exposure on breast
cancer risk reflects the ‘memory’ of breast epithelial stem
cells for genotoxic damage. Interestingly, a cohort of
women who survived A bomb exposure developed early-
onset breast cancer (<35 years of age), suggesting the
existence of a susceptible genetic subgroup [57]. It has
been suggested that this cohort may represent women
with pre-existing BRCA gene germline mutations [58].
Do such observations tie in with BRCA gene biology? If a
BRCA1+/– or BRCA2+/– mammary cell were to develop
checkpoint defects and undergo LOH at the relevant BRCA
locus early in breast development, then a number of daugh-
ter cells exhibiting this LOH event could be produced and
retained within the affected lobule. Cancer risk could be
multiplied in the breast epithelium by such an event, in pro-
portion to the number of daughter cells retained after the
LOH event (which might, at a maximum, constitute an entire
lobule, comprising millions of at-risk epithelial cells). By con-
trast, other rapidly proliferating epilthelia in which daughter
cells are rapidly shed (such as the colonic epithelium) would
not encounter this risk amplification mechanism. In this way,
the clonality of the breast epithelium may, in part, account
for the enhanced sensitivity of the breast to genotoxic
damage as a mechanism of carcinogenesis.
Furthermore, if the BRCA+/– genotype exhibits haploinsuf-
ficiency, then the risk of such early LOH events might beincreased. This model predicts that the years surrounding
puberty are particularly important for BRCA-linked disease,
and that the breast epithelium may develop detectable
genetic lesions in checkpoint and BRCA genes before the
end of puberty. Although there is relatively little information
that is directly pertinent to such mechanisms, one study
[59] suggested that LOH events connected with BRCA-
linked disease might occur early in breast development.
Mutagenesis models
At first glance, generic cellular functions such as DNA
repair/recombination would seem unlikely candidates for
having tissue-specific functions. However, the precise
genetic consequences of BRCA gene inactivation have
yet to be fully defined. Defects in DNA repair are fre-
quently accompanied by an increase in the mutation rate.
An interesting example of potentially tissue-specific effects
of mutagenesis came from a study of the impact of mis-
match repair (MMR) defects on colon cancer. MMR dys-
function gives rise to characteristic frame-shift mutations
across certain nucleotide repeat sequences. In MMR-
defective colon cancers, frame-shift mutations were
detected repeatedly within a purine-rich sequence in the
type II transforming growth factor-b receptor gene
sequence, resulting in its inactivation [60]. This suggested
that MMR defects might promote colon cancer specifically
by virtue of their characteristic mutagenic ‘signature’.
Could an analagous effect connect BRCA gene dysfunc-
tion to breast/ovarian cancer? There is as yet no indication
that  BRCA gene inactivation gives rise to a mutagenic
event that is capable of delivering such specificity.
However, ‘forward mutagenesis’ studies, which can
provide unbiased information regarding mutagenesis, have
not yet been reported for the BRCA genes. The full spec-
trum of mutagenesis attributable to BRCA gene inactiva-
tion is therefore unknown.
One similarity between the breast and the ovary is their
regulation by estrogenic hormones. A positive correlation
has been observed between estrogen exposure and
breast cancer risk [61]. This effect may in large part reflect
proliferative effects of estrogen upon its target tissues. In
addition, however, some estrogen metabolites, which
might be expected to accumulate in estrogen target
tissues, have been shown to chemically modify DNA in
vitro, and can promote carcinogenesis in some rodent
models [62,63]. An estrogen target tissue might therefore
suffer increased DNA damage directly from estrogen
metabolites, giving rise to a ‘remote carcinogenesis’
mechanism (i.e. although potentially carcinogenic in other
tissues, the pharmacokinetics of the carcinogen dictates a
restricted site of action in vivo).
A defect in recombination could amplify the carcinogenic
potential of this tissue-specific DNA damage. For example,
work in prokaryotes has revealed a key role for homolo-
gous recombination in maintaining genomic integrity after
DNA polymerase stalling/replication arrest (for review
[64]). Bulky DNA adducts, such as those formed by estro-
gen metabolites, might be expected to induce DNA poly-
merase stalling when encountered by the replication
machinery, placing particular stress on efficient recombi-
nation to prevent genomic instability. Error-prone recombi-
nation can give rise to chromosome translocation, LOH
events, and other large-scale genome rearrangements that
are characteristic of tumor cells (for review [65]). One can
imagine how tissue-specific DNA damage, BRCA gene
dysfunction, and the clonal expansion of breast epithelial
cells within the lobule (as discussed above) might collabo-
rate to promote breast cancer above other cancers in
BRCA-linked disease.
Clearly, the interplay between genotoxic damage and car-
cinogenesis is not limited to the breast. The gastrointesti-
nal tract, for example, must handle heavy loads of
genotoxic agents. However, this epithelium may be pro-
tected by the rapid shedding of epithelial cells, which
would ensure that only stem cells could potentially form
tumors. Such a difference in the physiology of these
epithelia may make the gastrointestinal tract less prone to
a recombination defect than the breast. At the same time,
experimental evidence for this concept is lacking.
The accumulation of a carcinogen at the target site would
seem to be a prerequisite for local carcinogen action. This
process might therefore also involve other genotoxic
agents that accumulate in the breast epithelium or sur-
rounding fat. Hints of this are seen in the property of
human mammary lipid extracts to promote single-stranded
DNA breaks in cultured primary human mammary epithelial
cells [66].
Transcriptional functions of BRCA1 and BRCA2
BRCA1 and BRCA2 have each been proposed to func-
tion as transcriptional regulators [67–70]. Indeed, BRCA1
and BRCA2 can form complexes with various transcription
factors and chromatin remodeling proteins [71–75]. If the
BRCA genes regulate the expression of a specific set of
target genes, then the identification of these targets might
reveal tissue-specific functions of BRCA1 or BRCA2 that
are relevant to breast and ovarian cancer. Several candi-
date target genes of BRCA1 have been identified.
Notably, some of these are DNA damage/stress respon-
sive genes and, in some cases, are p53 dependent
[76–78]. Both BRCA1 and BRCA2 can interact with p53
[79–81]. Overexpressed BRCA1 is toxic to cells and can
stabilize p53 [82,83]. In view of the repair functions of the
BRCA genes and the genetic interactions between p53
mutation and BRCA gene mutation, discussed above, the
relationship between BRCA gene products and p53 may
be complex. Evaluation of BRCA–p53 interactions may
reveal novel functions of p53 [46,50].
http://breast-cancer-research.com/content/2/5/324Transient overexpression of BRCA1 can modify estrogen
receptor-dependent promoter functions [84]. However,
estrogen receptor mutation is a frequent event in BRCA-
linked breast cancer, suggesting that tumorigenesis
caused by BRCA gene mutation affects pathways other
than those controlled by the estrogen receptor. A broader
analysis of the physiologic effects of BRCA gene products
on transcription functions may clarify which genes are
directly transcriptionally regulated by BRCA gene prod-
ucts, and which of these are relevant to tumor suppression.
Conclusion
It is not yet clear which properties of the BRCA genes
account for their tissue-specific actions. Genome stability
and transcription functions may each be relevant to BRCA
gene-mediated tumor suppression. How such functions
are applied to the breast and ovary may become clear
from a more detailed understanding of the biology of the
BRCA genes and of these epithelia.
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